ESC 365 - Summary - GLP-1 receptor agonists - The cardiovascular benefits beyond glucose control.

ESC Premium Access

Summary - GLP-1 receptor agonists - The cardiovascular benefits beyond glucose control.

Session: Outcomes of GLP-1 RA in diabetes and cardiovascular disease - Discussing the key opportunities for cardiology practice

Topic: Diabetes and the Heart

Speaker: Professor S. Jacob (Villingen, DE)

Organised by PACE-CME, Physicians' Academy for Cardiovascular Education, supported with an educational grant from Novo Nordisk

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Professor Stephan Jacob

Villingen (Germany)

8 presentations

0 follower

3 more presentations in this session

Introduction - Outcomes of GLP-1 RA in diabetes and cardiovascular disease - Discussing the key opportunities for cardiology practice

Speaker: Professor T. Luescher (London, GB)

Summary - Translating GLP-1 trial outcomes to cardiology practice - Which patients will benefit?

Speaker: Professor L. Ryden (Stockholm, SE)

Discussion - GLP-1 RA in diabetes and cardiovascular disease - What are the key opportunities for cardiology practice

Speaker: Professor T. Luescher (London, GB) Professor L. Ryden (Stockholm, SE) Professor S. Jacob (Villingen, DE)

Access the full session

Outcomes of GLP-1 RA in diabetes and cardiovascular disease - Discussing the key opportunities for cardiology practice

Speakers: Professor S. Jacob, Professor T. Luescher, Professor L. Ryden, Professor T. Luescher, Professor L. Ryden...

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources